<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4807">
  <stage>Registered</stage>
  <submitdate>13/08/2014</submitdate>
  <approvaldate>13/08/2014</approvaldate>
  <nctid>NCT02217475</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis</studytitle>
    <scientifictitle>CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis</scientifictitle>
    <utrn />
    <trialacronym>CENTAUR</trialacronym>
    <secondaryid>652-2-203</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nonalcoholic Steatohepatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cenicriviroc
Treatment: drugs - Placebo

Experimental: Cenicriviroc - Cenicriviroc 150mg tablet once daily in the morning with food for 2 years

Experimental: Placebo + Cenicriviroc - Placebo once daily in the morning with food for year 1 then Cenicriviroc 150 mg tablet once daily in the morning with food for year 2

Placebo Comparator: Placebo - Placebo once daily in the morning with food for 2 years


Treatment: drugs: Cenicriviroc
CVC 150 mg, administered orally once daily and taken every morning with food

Treatment: drugs: Placebo
Placebo administered orally once daily and taken every morning with food

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Histological improvement in nonalcoholic fatty liver disease (NAFLD) activity score (NAS) score with no concurrent worsening of fibrosis stage (NASH CRN system) - Defined by a minimum 2-point improvement in NAS with at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning</outcome>
      <timepoint>Year 1</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Complete resolution of steatohepatitis with no concurrent worsening of fibrosis stage</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in fibrosis by at least 1 stage (NASH CRN system) with no worsening of steatohepatitis</outcome>
      <timepoint>Years 1 and 2</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult subjects aged between 18-75

          -  Histological evidence of NASH, based on biopsy, with a NAS of &gt;= 4 with at least 1 in
             each component of NAS

          -  Histological evidence of liver fibrosis defined as NASH CRN System Stage 1 to 3

          -  Meeting any of the 3 major criteria (a, b, c):

               1. Documented evidence of type 2 diabetes mellitus

               2. High body mass index (&gt; 25 kg/m2) with at least one of the following criteria of
                  metabolic syndrome, as defined by the National Cholesterol Education Program:

                    -  Central obesity: waist circumference = 102 cm or 40 inches (male), = 88 cm
                       or 35 inches (female)

                    -  Dyslipidemia: Triglycerides = 1.7 mmol/L (150 mg/dL)

                    -  Dyslipidemia: High-density lipoprotein (HDL)-cholesterol &lt; 40 mg/dL (male),
                       &lt; 50 mg/dL (female)

                    -  Blood pressure = 130/85 mmHg (or currently being treated for hypertension)

                    -  Fasting plasma glucose = 6.1 mmol/L (110 mg/dL)

               3. Bridging fibrosis (NASH CRN Stage 3) and/or definite NASH (NAS = 5)

          -  Agree to have one liver biopsy at Screening, one at Year 1, and one at the end of
             study treatment (Year 2)

          -  AST and ALT = 5 × upper limit of normal (ULN)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Hepatitis B surface Antigen (HBsAg) positive

          -  Hepatitis C antibody (HCVAb) positive with the following 2 exceptions:

               1. Subjects previously treated for viral hepatitis C with at least a 1-year period
                  since documented sustained virologic response at Week 12 (post-treatment) may be
                  eligible if all other eligibility criteria are met

               2. Subjects with presence of hepatitis C antibody but negative hepatitis C virus RNA
                  without treatment (i.e., spontaneous clearance) may be eligible if all other
                  eligibility criteria are met

          -  Prior or planned liver transplantation

          -  Other known causes of chronic liver disease, including alcoholic liver disease

          -  History of cirrhosis and/or hepatic decompensation including ascites, hepatic
             encephalopathy or variceal bleeding

          -  Alcohol consumption greater than 21 units/week for males or 14 units/week for females
             (one unit of alcohol is ½ pint of beer [285 mL], 1 glass of spirits [25 mL] or 1 glass
             of wine [125 mL])

          -  HIV-1 or HIV-2 infection

          -  Weight reduction through bariatric surgery in the past 5 years or planned during the
             conduct of the study (including gastric banding)

          -  Females who are pregnant or breastfeeding

          -  Any other clinically significant disorders or prior therapy that, in the opinion of
             the investigator, would make the subject unsuitable for the study or unable to comply
             with the dosing and protocol requirements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>289</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,QLD,SA,VIC,WA</recruitmentstate>
    <hospital> - Garran</hospital>
    <hospital> - Herston</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Bedford Park</hospital>
    <hospital> - Clayton</hospital>
    <hospital> - Heidelberg</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Perth</hospital>
    <postcode> - Garran</postcode>
    <postcode> - Herston</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koeln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lubeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>New Territories</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rozzano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Myslowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Rzeszow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle, Tyne and Wear</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Portsmouth</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Tobira Therapeutics, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether Cenicriviroc is effective and safe in the
      treatment of nonalcoholic steatohepatitis (NASH) in adult subjects with liver fibrosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02217475</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eric Lefebvre, MD</name>
      <address>Tobira Therapeutics, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>